Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,19246725,patch strengths,"Rivastigmine patch strengths were 4.6 mg/24 h (5 cm2, 9 mg rivastigmine loaded dose), 9.5 mg/24 h (10 cm2, 18 mg), and 13.3 mg/24 h (15 cm2, 27 mg) (per label) or 7.0 mg/24 h (7.5 cm2, 13.5 mg) as a fall-back dose.",Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19246725/),[mg] / [24·h],4.6,62,DB00989,Rivastigmine
,19246725,patch strengths,"Rivastigmine patch strengths were 4.6 mg/24 h (5 cm2, 9 mg rivastigmine loaded dose), 9.5 mg/24 h (10 cm2, 18 mg), and 13.3 mg/24 h (15 cm2, 27 mg) (per label) or 7.0 mg/24 h (7.5 cm2, 13.5 mg) as a fall-back dose.",Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19246725/),mg,9.5,63,DB00989,Rivastigmine
,19246725,patch strengths,"Rivastigmine patch strengths were 4.6 mg/24 h (5 cm2, 9 mg rivastigmine loaded dose), 9.5 mg/24 h (10 cm2, 18 mg), and 13.3 mg/24 h (15 cm2, 27 mg) (per label) or 7.0 mg/24 h (7.5 cm2, 13.5 mg) as a fall-back dose.",Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19246725/),[mg] / [24·h],13.3,64,DB00989,Rivastigmine
,19246725,patch strengths,"Rivastigmine patch strengths were 4.6 mg/24 h (5 cm2, 9 mg rivastigmine loaded dose), 9.5 mg/24 h (10 cm2, 18 mg), and 13.3 mg/24 h (15 cm2, 27 mg) (per label) or 7.0 mg/24 h (7.5 cm2, 13.5 mg) as a fall-back dose.",Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19246725/),[mg] / [24],7.0,65,DB00989,Rivastigmine
,18589553,flow rate,"The chromatographic separation was achieved with a reverse phase monomeric column C18 (4.6 x 250 mm, 5 microm) and the mobile phase consisted of acetonitrile and 20 mmol/L phosphate buffer pH 3.0 (25:75) with a flow rate of 1 mL/min.",Fluorimetric determination of rivastigmine in rat plasma by a reverse phase--high performance liquid chromatographic method. Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589553/),[ml] / [min],1,10730,DB00989,Rivastigmine
,33680013,Maximum brain concentration,"Maximum brain concentration after i.m. administration was reached in the 36 (8.34 ± 0.34 ng/mL) and 17 minute (6.18 ± 0.40 ng/mL), respectively for donepezil and rivastigmine.",Donepezil and Rivastigmine: Pharmacokinetic Profile and Brain-targeting After Intramuscular Administration in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33680013/),[ng] / [ml],8.34,10977,DB00989,Rivastigmine
,33680013,Maximum brain concentration,"Maximum brain concentration after i.m. administration was reached in the 36 (8.34 ± 0.34 ng/mL) and 17 minute (6.18 ± 0.40 ng/mL), respectively for donepezil and rivastigmine.",Donepezil and Rivastigmine: Pharmacokinetic Profile and Brain-targeting After Intramuscular Administration in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33680013/),[ng] / [ml],6.18,10978,DB00989,Rivastigmine
,33435009,zeta potential,"The average size of the prepared blank (MCM-41B) and drug-loaded MSNs (MCM-41L) was 114 ± 2.0 and 145 ± 0.4 nm with the zeta potential of approximately -43.5 ± 1.1 and -37.6 ± 1.4 mV, respectively.",MCM-41 Nanoparticles for Brain Delivery: Better Choline-Esterase and Amyloid Formation Inhibition with Improved Kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435009/),mv,43.5,19842,DB00989,Rivastigmine
,33435009,zeta potential,"The average size of the prepared blank (MCM-41B) and drug-loaded MSNs (MCM-41L) was 114 ± 2.0 and 145 ± 0.4 nm with the zeta potential of approximately -43.5 ± 1.1 and -37.6 ± 1.4 mV, respectively.",MCM-41 Nanoparticles for Brain Delivery: Better Choline-Esterase and Amyloid Formation Inhibition with Improved Kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435009/),mv,-,19843,DB00989,Rivastigmine
,33435009,zeta potential,"The average size of the prepared blank (MCM-41B) and drug-loaded MSNs (MCM-41L) was 114 ± 2.0 and 145 ± 0.4 nm with the zeta potential of approximately -43.5 ± 1.1 and -37.6 ± 1.4 mV, respectively.",MCM-41 Nanoparticles for Brain Delivery: Better Choline-Esterase and Amyloid Formation Inhibition with Improved Kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435009/),mv,37.6,19844,DB00989,Rivastigmine
,33435009,entrapment efficiency,MCM-41L exhibited an average entrapment efficiency of 88%.,MCM-41 Nanoparticles for Brain Delivery: Better Choline-Esterase and Amyloid Formation Inhibition with Improved Kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435009/),%,88,19845,DB00989,Rivastigmine
,33435009,AUC,In vivo pharmacokinetics in Wistar rats revealed that the AUC and mean residence time (MRT) for MCM-41L was sustained and significantly higher (p < 0.05) (780 ± 3.30 ng/L; 5.49 ± 0.25 h) compared to RTG solution (430 ± 3.50 ng/L; 0.768 ± 0.17 h).,MCM-41 Nanoparticles for Brain Delivery: Better Choline-Esterase and Amyloid Formation Inhibition with Improved Kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435009/),[ng] / [l],780,19846,DB00989,Rivastigmine
,33435009,AUC,In vivo pharmacokinetics in Wistar rats revealed that the AUC and mean residence time (MRT) for MCM-41L was sustained and significantly higher (p < 0.05) (780 ± 3.30 ng/L; 5.49 ± 0.25 h) compared to RTG solution (430 ± 3.50 ng/L; 0.768 ± 0.17 h).,MCM-41 Nanoparticles for Brain Delivery: Better Choline-Esterase and Amyloid Formation Inhibition with Improved Kinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435009/),[ng] / [l],430,19847,DB00989,Rivastigmine
,33435009,mean residence time (MRT),In vivo pharmacokinetics in Wistar rats revealed that the AUC and mean residence time (MRT) for MCM-41L was sustained and significantly higher (p < 0.05) (780 ± 3.30 ng/L; 5.49 ± 0.25 h) compared to RTG solution (430 ± 3.50 ng/L; 0.768 ± 0.17 h).,MCM-41 Nanoparticles for Brain Delivery: Better Choline-Esterase and Amyloid Formation Inhibition with Improved Kinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435009/),h,5.49,19848,DB00989,Rivastigmine
,33435009,mean residence time (MRT),In vivo pharmacokinetics in Wistar rats revealed that the AUC and mean residence time (MRT) for MCM-41L was sustained and significantly higher (p < 0.05) (780 ± 3.30 ng/L; 5.49 ± 0.25 h) compared to RTG solution (430 ± 3.50 ng/L; 0.768 ± 0.17 h).,MCM-41 Nanoparticles for Brain Delivery: Better Choline-Esterase and Amyloid Formation Inhibition with Improved Kinetics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435009/),h,0.768,19849,DB00989,Rivastigmine
,17522596,Cmax,"The patch showed lower Cmax (ca. 30% lower at 20 cm2, 19.5 versus 29.3 ng/ml), longer tmax (8.0 versus 1.0 h), and greater AUC (ca. 1.8-fold at 20 cm2, 345 versus 191 ng x h/ml) compared with the 6 mg Q12H capsule dose, with markedly less fluctuation between peak and trough plasma levels (80% at 20 cm2 versus 620% at 1.5 mg Q12H).",Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17522596/),[ng] / [ml],19.5,27892,DB00989,Rivastigmine
,17522596,Cmax,"The patch showed lower Cmax (ca. 30% lower at 20 cm2, 19.5 versus 29.3 ng/ml), longer tmax (8.0 versus 1.0 h), and greater AUC (ca. 1.8-fold at 20 cm2, 345 versus 191 ng x h/ml) compared with the 6 mg Q12H capsule dose, with markedly less fluctuation between peak and trough plasma levels (80% at 20 cm2 versus 620% at 1.5 mg Q12H).",Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17522596/),[ng] / [ml],29.3,27893,DB00989,Rivastigmine
,17522596,tmax,"The patch showed lower Cmax (ca. 30% lower at 20 cm2, 19.5 versus 29.3 ng/ml), longer tmax (8.0 versus 1.0 h), and greater AUC (ca. 1.8-fold at 20 cm2, 345 versus 191 ng x h/ml) compared with the 6 mg Q12H capsule dose, with markedly less fluctuation between peak and trough plasma levels (80% at 20 cm2 versus 620% at 1.5 mg Q12H).",Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17522596/),h,8.0,27894,DB00989,Rivastigmine
,17522596,tmax,"The patch showed lower Cmax (ca. 30% lower at 20 cm2, 19.5 versus 29.3 ng/ml), longer tmax (8.0 versus 1.0 h), and greater AUC (ca. 1.8-fold at 20 cm2, 345 versus 191 ng x h/ml) compared with the 6 mg Q12H capsule dose, with markedly less fluctuation between peak and trough plasma levels (80% at 20 cm2 versus 620% at 1.5 mg Q12H).",Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17522596/),h,1.0,27895,DB00989,Rivastigmine
,17522596,AUC,"The patch showed lower Cmax (ca. 30% lower at 20 cm2, 19.5 versus 29.3 ng/ml), longer tmax (8.0 versus 1.0 h), and greater AUC (ca. 1.8-fold at 20 cm2, 345 versus 191 ng x h/ml) compared with the 6 mg Q12H capsule dose, with markedly less fluctuation between peak and trough plasma levels (80% at 20 cm2 versus 620% at 1.5 mg Q12H).",Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17522596/),[h·ng] / [ml],345,27896,DB00989,Rivastigmine
,17522596,AUC,"The patch showed lower Cmax (ca. 30% lower at 20 cm2, 19.5 versus 29.3 ng/ml), longer tmax (8.0 versus 1.0 h), and greater AUC (ca. 1.8-fold at 20 cm2, 345 versus 191 ng x h/ml) compared with the 6 mg Q12H capsule dose, with markedly less fluctuation between peak and trough plasma levels (80% at 20 cm2 versus 620% at 1.5 mg Q12H).",Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17522596/),[h·ng] / [ml],191,27897,DB00989,Rivastigmine
,28670911,Area under the concentration-time curve from time zero to time t (AUC0- t),"Area under the concentration-time curve from time zero to time t (AUC0- t) and area under the concentration-time curve from time zero to infinity (AUC0-∞) for Exelon (mean [standard deviation], h·ng/mL) were 126.40 (56.95) and 129.46 (59.94), respectively, while they were 122.73 (43.46) and 125.08 (45.39) for rivastigmine.",Bioequivalence Study of Rivastigmine 6 mg Capsules (Single Dose) in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28670911/),[h·ng] / [ml],126.40,38235,DB00989,Rivastigmine
,28670911,Area under the concentration-time curve from time zero to time t (AUC0- t),"Area under the concentration-time curve from time zero to time t (AUC0- t) and area under the concentration-time curve from time zero to infinity (AUC0-∞) for Exelon (mean [standard deviation], h·ng/mL) were 126.40 (56.95) and 129.46 (59.94), respectively, while they were 122.73 (43.46) and 125.08 (45.39) for rivastigmine.",Bioequivalence Study of Rivastigmine 6 mg Capsules (Single Dose) in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28670911/),[h·ng] / [ml],122.73,38236,DB00989,Rivastigmine
,28670911,area under the concentration-time curve from time zero to infinity (AUC0-∞),"Area under the concentration-time curve from time zero to time t (AUC0- t) and area under the concentration-time curve from time zero to infinity (AUC0-∞) for Exelon (mean [standard deviation], h·ng/mL) were 126.40 (56.95) and 129.46 (59.94), respectively, while they were 122.73 (43.46) and 125.08 (45.39) for rivastigmine.",Bioequivalence Study of Rivastigmine 6 mg Capsules (Single Dose) in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28670911/),[h·ng] / [ml],126.40,38237,DB00989,Rivastigmine
,28670911,area under the concentration-time curve from time zero to infinity (AUC0-∞),"Area under the concentration-time curve from time zero to time t (AUC0- t) and area under the concentration-time curve from time zero to infinity (AUC0-∞) for Exelon (mean [standard deviation], h·ng/mL) were 126.40 (56.95) and 129.46 (59.94), respectively, while they were 122.73 (43.46) and 125.08 (45.39) for rivastigmine.",Bioequivalence Study of Rivastigmine 6 mg Capsules (Single Dose) in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28670911/),[h·ng] / [ml],129.46,38238,DB00989,Rivastigmine
,28670911,area under the concentration-time curve from time zero to infinity (AUC0-∞),"Area under the concentration-time curve from time zero to time t (AUC0- t) and area under the concentration-time curve from time zero to infinity (AUC0-∞) for Exelon (mean [standard deviation], h·ng/mL) were 126.40 (56.95) and 129.46 (59.94), respectively, while they were 122.73 (43.46) and 125.08 (45.39) for rivastigmine.",Bioequivalence Study of Rivastigmine 6 mg Capsules (Single Dose) in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28670911/),[h·ng] / [ml],125.08,38239,DB00989,Rivastigmine
,19998576,AUC,"Compared to male rats, female rats exhibited higher plasma rivastigmine levels showing significantly (p < 0.05) larger AUC (226.77 vs. 149.68 ng h/ml), Vd (6.70 vs. 4.13 L), t1/2 (0.84 vs. 0.34 h) and a lower CL (5.51 vs. 8.35 L/h).",Gender differences in the pharmacokinetics of rivastigmine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998576/),[h·ng] / [ml],226.77,42639,DB00989,Rivastigmine
,19998576,AUC,"Compared to male rats, female rats exhibited higher plasma rivastigmine levels showing significantly (p < 0.05) larger AUC (226.77 vs. 149.68 ng h/ml), Vd (6.70 vs. 4.13 L), t1/2 (0.84 vs. 0.34 h) and a lower CL (5.51 vs. 8.35 L/h).",Gender differences in the pharmacokinetics of rivastigmine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998576/),[h·ng] / [ml],149.68,42640,DB00989,Rivastigmine
,19998576,Vd,"Compared to male rats, female rats exhibited higher plasma rivastigmine levels showing significantly (p < 0.05) larger AUC (226.77 vs. 149.68 ng h/ml), Vd (6.70 vs. 4.13 L), t1/2 (0.84 vs. 0.34 h) and a lower CL (5.51 vs. 8.35 L/h).",Gender differences in the pharmacokinetics of rivastigmine in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998576/),l,6.70,42641,DB00989,Rivastigmine
,19998576,Vd,"Compared to male rats, female rats exhibited higher plasma rivastigmine levels showing significantly (p < 0.05) larger AUC (226.77 vs. 149.68 ng h/ml), Vd (6.70 vs. 4.13 L), t1/2 (0.84 vs. 0.34 h) and a lower CL (5.51 vs. 8.35 L/h).",Gender differences in the pharmacokinetics of rivastigmine in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998576/),l,4.13,42642,DB00989,Rivastigmine
,19998576,t1/2,"Compared to male rats, female rats exhibited higher plasma rivastigmine levels showing significantly (p < 0.05) larger AUC (226.77 vs. 149.68 ng h/ml), Vd (6.70 vs. 4.13 L), t1/2 (0.84 vs. 0.34 h) and a lower CL (5.51 vs. 8.35 L/h).",Gender differences in the pharmacokinetics of rivastigmine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998576/),h,0.84,42643,DB00989,Rivastigmine
,19998576,t1/2,"Compared to male rats, female rats exhibited higher plasma rivastigmine levels showing significantly (p < 0.05) larger AUC (226.77 vs. 149.68 ng h/ml), Vd (6.70 vs. 4.13 L), t1/2 (0.84 vs. 0.34 h) and a lower CL (5.51 vs. 8.35 L/h).",Gender differences in the pharmacokinetics of rivastigmine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998576/),h,0.34,42644,DB00989,Rivastigmine
,19998576,CL,"Compared to male rats, female rats exhibited higher plasma rivastigmine levels showing significantly (p < 0.05) larger AUC (226.77 vs. 149.68 ng h/ml), Vd (6.70 vs. 4.13 L), t1/2 (0.84 vs. 0.34 h) and a lower CL (5.51 vs. 8.35 L/h).",Gender differences in the pharmacokinetics of rivastigmine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998576/),[l] / [h],5.51,42645,DB00989,Rivastigmine
,19998576,CL,"Compared to male rats, female rats exhibited higher plasma rivastigmine levels showing significantly (p < 0.05) larger AUC (226.77 vs. 149.68 ng h/ml), Vd (6.70 vs. 4.13 L), t1/2 (0.84 vs. 0.34 h) and a lower CL (5.51 vs. 8.35 L/h).",Gender differences in the pharmacokinetics of rivastigmine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998576/),[l] / [h],8.35,42646,DB00989,Rivastigmine
,19998576,elimination rate constant,The male rats had a 2.5 fold greater elimination rate constant than female rats (2.02 vs. 0.82 h(-1)).,Gender differences in the pharmacokinetics of rivastigmine in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998576/),1/[h],2.02,42647,DB00989,Rivastigmine
,19998576,elimination rate constant,The male rats had a 2.5 fold greater elimination rate constant than female rats (2.02 vs. 0.82 h(-1)).,Gender differences in the pharmacokinetics of rivastigmine in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19998576/),1/[h],0.82,42648,DB00989,Rivastigmine
,30156844,root-mean-square roughness ( Rq),"Atomic force microscopic results revealed that the root-mean-square roughness ( Rq) and surface roughness ( Ra) were 6.31 and 5.27 nm, respectively, along with other parameters, Skewness and Kurtosis, which were 0.522 and 2.50, respectively.",Boosted Memory and Improved Brain Bioavailability of Rivastigmine: Targeting Effort to the Brain Using Covalently Tethered Lower Generation PAMAM Dendrimers with Lactoferrin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30156844/),nm,6.31,48341,DB00989,Rivastigmine
,30156844,surface roughness ( Ra),"Atomic force microscopic results revealed that the root-mean-square roughness ( Rq) and surface roughness ( Ra) were 6.31 and 5.27 nm, respectively, along with other parameters, Skewness and Kurtosis, which were 0.522 and 2.50, respectively.",Boosted Memory and Improved Brain Bioavailability of Rivastigmine: Targeting Effort to the Brain Using Covalently Tethered Lower Generation PAMAM Dendrimers with Lactoferrin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30156844/),nm,5.27,48342,DB00989,Rivastigmine
,22224039,flow rate,"The chromatographic separation was achieved with a column inertsil ODS-3V and a mobile phase consisting of ammonium acetate buffer (20 mM, pH 4.5) and acetonitrile (76:24, v/v) delivered at a flow rate of 1 ml/min.",High performance liquid chromatographic fluorescence detection method for the quantification of rivastigmine in rat plasma and brain: application to preclinical pharmacokinetic studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22224039/),[ml] / [min],1,56022,DB00989,Rivastigmine
,9673779,tmax,The rate and onset of absorption were rapid (tmax 1.3 +/- 0.58 h) and the extent of absorption was essentially complete.,"Disposition of SDZ ENA 713, an acetylcholinesterase inhibitor, in the rabbit. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673779/),h,1.3,57417,DB00989,Rivastigmine
,9673779,Vss,"Following intravenous administration, SDZ ENA 713 was extensively distributed (Vss = 3.1 L kg-1) and rapidly cleared (Cl = 2.7 L h-1 kg-1).","Disposition of SDZ ENA 713, an acetylcholinesterase inhibitor, in the rabbit. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673779/),[l] / [kg],3.1,57418,DB00989,Rivastigmine
,9673779,Cl,"Following intravenous administration, SDZ ENA 713 was extensively distributed (Vss = 3.1 L kg-1) and rapidly cleared (Cl = 2.7 L h-1 kg-1).","Disposition of SDZ ENA 713, an acetylcholinesterase inhibitor, in the rabbit. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673779/),[l] / [h·kg],2.7,57419,DB00989,Rivastigmine
,9673779,f,"In pregnant rabbits receiving multiple oral doses, the fetus to placentae tissue ratio of radioactivity averaged 0.5.","Disposition of SDZ ENA 713, an acetylcholinesterase inhibitor, in the rabbit. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673779/),,0.5,57420,DB00989,Rivastigmine
,9673779,tissue ratio of radioactivity,"In pregnant rabbits receiving multiple oral doses, the fetus to placentae tissue ratio of radioactivity averaged 0.5.","Disposition of SDZ ENA 713, an acetylcholinesterase inhibitor, in the rabbit. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673779/),,0.5,57421,DB00989,Rivastigmine
,9673779,tmax,Passage of radioactivity from blood into milk was rapid (tmax = 2 h) and the milk:blood AUC ratio of radioactivity averaged 1.5.,"Disposition of SDZ ENA 713, an acetylcholinesterase inhibitor, in the rabbit. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673779/),h,2,57422,DB00989,Rivastigmine
,9673779,AUC ratio of radioactivity,Passage of radioactivity from blood into milk was rapid (tmax = 2 h) and the milk:blood AUC ratio of radioactivity averaged 1.5.,"Disposition of SDZ ENA 713, an acetylcholinesterase inhibitor, in the rabbit. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673779/),,1.5,57423,DB00989,Rivastigmine
,9673779,Cmax,"No unchanged SDZ ENA 713 was detected in the milk samples; however, there were measurable concentrations of the phenolic metabolite (Cmax = 82.9 ng mL-1).","Disposition of SDZ ENA 713, an acetylcholinesterase inhibitor, in the rabbit. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673779/),[ng] / [ml],82.9,57424,DB00989,Rivastigmine
,9673779,milk to blood ratio,The milk to blood ratio of the phenolic metabolite averaged 2.3.,"Disposition of SDZ ENA 713, an acetylcholinesterase inhibitor, in the rabbit. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9673779/),,2.3,57425,DB00989,Rivastigmine
,9576639,maximum mean inhibition,The 6 mg bid treatment group showed a maximum mean inhibition of 62% at 5.6 h post-dose.,Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9576639/),%,62,57788,DB00989,Rivastigmine
,17389556,t(max),Median t(max) was 16 hours for all sites except the thigh (22 hours).,Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17389556/),h,16,58217,DB00989,Rivastigmine
,17389556,t(max),Median t(max) was 16 hours for all sites except the thigh (22 hours).,Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17389556/),h,22,58218,DB00989,Rivastigmine
,33640502,ratio,"The RVS in optimized patch was basically permeated at a uniform rate, and the ratio of the skin permeation amount (2803.38 ± 153.85 μg/cm2) in 72 hours to that of the control group (1000.89 ± 62.45 μg/cm2) was 2.8.",Development of long-acting rivastigmine drug-in-adhesive patch utilizing ion-pair strategy and characterization of controlled release mechanism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33640502/),[μg] / [cm2],2803.38,69317,DB00989,Rivastigmine
,33640502,AUCoptimized,"The plasma concentration of RVS was stable for 72 hours in vivo (AUCoptimized = 5721.30 ± 1994.87 h ng/mL, MRT0-t = 29.55 ± 2.49 h), and Cmax was significantly controlled.",Development of long-acting rivastigmine drug-in-adhesive patch utilizing ion-pair strategy and characterization of controlled release mechanism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33640502/),[h·ng] / [ml],5721.30,69318,DB00989,Rivastigmine
,33640502,MRT0-t,"The plasma concentration of RVS was stable for 72 hours in vivo (AUCoptimized = 5721.30 ± 1994.87 h ng/mL, MRT0-t = 29.55 ± 2.49 h), and Cmax was significantly controlled.",Development of long-acting rivastigmine drug-in-adhesive patch utilizing ion-pair strategy and characterization of controlled release mechanism. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33640502/),h,29.55,69319,DB00989,Rivastigmine
,32594811,steady-state flux,The ex vivo permeation study showed that liposomes provided steady-state flux 0.11 ± 0.01 mg/cm.h that were more than 2-fold the aqueous control.,Dermal pharmacokinetics of rivastigmine-loaded liposomes: an ex vivo-in vivo correlation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32594811/),[mg] / [cm·h],0.11,70097,DB00989,Rivastigmine
,32594811,Cmax,"In the in vivo experiments, after topical application of optimized rivastigmine liposomes, the Cmax 208 ng/ml and AUC0-24 3605 (ng.h/ml) were also significantly higher than the control group (both p < 0.01).",Dermal pharmacokinetics of rivastigmine-loaded liposomes: an ex vivo-in vivo correlation study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32594811/),[ng] / [ml],208,70098,DB00989,Rivastigmine
,32594811,AUC0-24,"In the in vivo experiments, after topical application of optimized rivastigmine liposomes, the Cmax 208 ng/ml and AUC0-24 3605 (ng.h/ml) were also significantly higher than the control group (both p < 0.01).",Dermal pharmacokinetics of rivastigmine-loaded liposomes: an ex vivo-in vivo correlation study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32594811/),[h·ng] / [ml],3605,70099,DB00989,Rivastigmine
,24363716,flow-rate,Analyses were run at a flow-rate of 1.3 mL/min at of 50°C.,High-performance liquid chromatographic determination of rivastigmine in human plasma for application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363716/),[ml] / [min],1.3,72037,DB00989,Rivastigmine
,24363716,recovery,"The recovery was 90.8% and 95.7% for rivastigmine and the internal standard donepezil, respectively.",High-performance liquid chromatographic determination of rivastigmine in human plasma for application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363716/),%,90.8,72038,DB00989,Rivastigmine
,24363716,recovery,"The recovery was 90.8% and 95.7% for rivastigmine and the internal standard donepezil, respectively.",High-performance liquid chromatographic determination of rivastigmine in human plasma for application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363716/),%,95.7,72039,DB00989,Rivastigmine
,24363716,detection limit,"The method was specific and sensitive, with a quantification limit of 0.5 ng/mL and a detection limit of 0.2 ng/mL in plasma.",High-performance liquid chromatographic determination of rivastigmine in human plasma for application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363716/),[ng] / [ml],0.2,72040,DB00989,Rivastigmine
,23455202,loading rate,HAM has showed the loading rate as 1.35% (w/w) and yielded 42% with mean particle size at 72.6 μm.,Preparation and in vitro and in vivo evaluation of HupA PLGA microsphere. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23455202/),%,1.35,74536,DB00989,Rivastigmine
,11929322,time to peak plasma concentration,"Following oral administration of a single 6 mg capsule, rivastigmine is rapidly absorbed with an average time to peak plasma concentration of about 1 hour and an average peak concentration of about 25.6 g/L.",Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11929322/),h,1,88996,DB00989,Rivastigmine
,11929322,peak concentration,"Following oral administration of a single 6 mg capsule, rivastigmine is rapidly absorbed with an average time to peak plasma concentration of about 1 hour and an average peak concentration of about 25.6 g/L.",Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11929322/),[g] / [l],25.6,88997,DB00989,Rivastigmine
,11929322,absolute bioavailability,"By a noncompartmental approach, the absolute bioavailability of the 6 mg oral dose of rivastigmine was 71.7% when compared with a 2mg intravenous infusion normalised for dose.",Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11929322/),%,71.7,88998,DB00989,Rivastigmine
,11929322,absolute bioavailability,"By using a population pharmacokinetic model with Michaelis-Menten elimination, absolute bioavailability was estimated at 60.2%.",Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11929322/),%,60.2,88999,DB00989,Rivastigmine
,11929322,terminal elimination half-life,The average terminal elimination half-life of rivastigmine ranged from 1.4 to 1.7 hours for both treatments.,Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11929322/),h,1.4 to 1.7,89000,DB00989,Rivastigmine
,11929322,absolute bioavailability,"A noncompartmental approach and a compartmental approach based on a population pharmacokinetic model with Michaelis-Menten elimination yielded comparable values, 71.7% and 60.2% respectively, for the absolute bioavailability of a single 6 mg oral dose of rivastigmine.",Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11929322/),%,60.2,89001,DB00989,Rivastigmine
,24730237,particle size,"The mean particle size, zeta potential and entrapment efficiency of drug loaded NPs were found to be 142.2 +/- 21.3 nm, +4.85 mV and 60.72 +/- 3.72% respectively.",Novel L-lactide-depsipeptide polymeric carrier for enhanced brain uptake of rivastigmine in treatment of Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24730237/),nm,142.2,94527,DB00989,Rivastigmine
,24730237,entrapment efficiency,"The mean particle size, zeta potential and entrapment efficiency of drug loaded NPs were found to be 142.2 +/- 21.3 nm, +4.85 mV and 60.72 +/- 3.72% respectively.",Novel L-lactide-depsipeptide polymeric carrier for enhanced brain uptake of rivastigmine in treatment of Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24730237/),,60.,94528,DB00989,Rivastigmine
,17296337,m/z,"The mass transition ion-pair was followed as m/z 251.20-->206.10, 86.20 for rivastigmine and m/z 308.10-->235.10 for zolpidem.",A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296337/),,251.20,97928,DB00989,Rivastigmine
,17296337,m/z,"The mass transition ion-pair was followed as m/z 251.20-->206.10, 86.20 for rivastigmine and m/z 308.10-->235.10 for zolpidem.",A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296337/),,206.10,97929,DB00989,Rivastigmine
,17296337,m/z,"The mass transition ion-pair was followed as m/z 251.20-->206.10, 86.20 for rivastigmine and m/z 308.10-->235.10 for zolpidem.",A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296337/),,86.20,97930,DB00989,Rivastigmine
,17296337,m/z,"The mass transition ion-pair was followed as m/z 251.20-->206.10, 86.20 for rivastigmine and m/z 308.10-->235.10 for zolpidem.",A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296337/),,308.10,97931,DB00989,Rivastigmine
,17296337,m/z,"The mass transition ion-pair was followed as m/z 251.20-->206.10, 86.20 for rivastigmine and m/z 308.10-->235.10 for zolpidem.",A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296337/),,235.10,97932,DB00989,Rivastigmine
,17296337,overall recoveries,"The overall recoveries for rivastigmine and zolpidem were 86.28% and 87.57%, respectively.",A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296337/),%,86.28,97933,DB00989,Rivastigmine
,17296337,overall recoveries,"The overall recoveries for rivastigmine and zolpidem were 86.28% and 87.57%, respectively.",A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296337/),%,87.57,97934,DB00989,Rivastigmine
,17296337,total run time,The total run time was 2.0 min.,A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17296337/),min,2.0,97935,DB00989,Rivastigmine
,15145967,AUV(0- infinity ),"Compared with oral administration (AUV(0- infinity ) = 21 ng*h/mL, C(max) = 12.8 ng/mL, and t(max) = 0.87 h), delivery of the drug directly into the ileum, jejunum, and ascending colon did not change the extent of absorption, but the time to peak concentration appeared to be smaller (mean t(max) ranged from 0.4-0.6 h, with no change in C(max)).",Absorption of rivastigmine from different regions of the gastrointestinal tract in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15145967/),[h·ng] / [ml],21,101792,DB00989,Rivastigmine
,15145967,C(max),"Compared with oral administration (AUV(0- infinity ) = 21 ng*h/mL, C(max) = 12.8 ng/mL, and t(max) = 0.87 h), delivery of the drug directly into the ileum, jejunum, and ascending colon did not change the extent of absorption, but the time to peak concentration appeared to be smaller (mean t(max) ranged from 0.4-0.6 h, with no change in C(max)).",Absorption of rivastigmine from different regions of the gastrointestinal tract in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15145967/),[ng] / [ml],12.8,101793,DB00989,Rivastigmine
,15145967,t(max),"Compared with oral administration (AUV(0- infinity ) = 21 ng*h/mL, C(max) = 12.8 ng/mL, and t(max) = 0.87 h), delivery of the drug directly into the ileum, jejunum, and ascending colon did not change the extent of absorption, but the time to peak concentration appeared to be smaller (mean t(max) ranged from 0.4-0.6 h, with no change in C(max)).",Absorption of rivastigmine from different regions of the gastrointestinal tract in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15145967/),h,0.87,101794,DB00989,Rivastigmine
,15145967,t(max),"Compared with oral administration (AUV(0- infinity ) = 21 ng*h/mL, C(max) = 12.8 ng/mL, and t(max) = 0.87 h), delivery of the drug directly into the ileum, jejunum, and ascending colon did not change the extent of absorption, but the time to peak concentration appeared to be smaller (mean t(max) ranged from 0.4-0.6 h, with no change in C(max)).",Absorption of rivastigmine from different regions of the gastrointestinal tract in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15145967/),h,0.4-0.6,101795,DB00989,Rivastigmine
,11583476,apparent clearance,"The apparent clearance and volume of distribution (plasma) of rivastigmine were estimated to be 120 L/h and 236 L, respectively.","Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583476/),[l] / [h],120,107742,DB00989,Rivastigmine
,11583476,volume of distribution (plasma),"The apparent clearance and volume of distribution (plasma) of rivastigmine were estimated to be 120 L/h and 236 L, respectively.","Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583476/),l,236,107743,DB00989,Rivastigmine
,11583476,relative bioavailability,The relative bioavailability at the 6 mg dose was about 140%.,"Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583476/),%,140,107744,DB00989,Rivastigmine
,11583476,clearance,The metabolite had a clearance of about 100 L/h and a volume of distribution of 256 L.,"Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583476/),[l] / [h],100,107745,DB00989,Rivastigmine
,11583476,volume of distribution,The metabolite had a clearance of about 100 L/h and a volume of distribution of 256 L.,"Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583476/),l,256,107746,DB00989,Rivastigmine
,11583476,half-life,"The kinetics of the parent and metabolite in CSF showed an equilibration half-life of about 0.2 and 0.5 hours, respectively.","Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583476/),h,0.2,107747,DB00989,Rivastigmine
,11583476,half-life,"The kinetics of the parent and metabolite in CSF showed an equilibration half-life of about 0.2 and 0.5 hours, respectively.","Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583476/),h,0.5,107748,DB00989,Rivastigmine
,33466880,MF/D ratio,The optimal RV-ISM system with the highest desirability value (0.74) was predicted to have an MF/D ratio of 11.7:1 (w/w) and an S/P ratio of 1.64:1 (w/w).,In Situ-Forming Microparticles for Controlled Release of Rivastigmine: In Vitro Optimization and In Vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33466880/),:1,11.7,110084,DB00989,Rivastigmine
,33466880,S/P ratio,The optimal RV-ISM system with the highest desirability value (0.74) was predicted to have an MF/D ratio of 11.7:1 (w/w) and an S/P ratio of 1.64:1 (w/w).,In Situ-Forming Microparticles for Controlled Release of Rivastigmine: In Vitro Optimization and In Vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33466880/),:1,1.64,110085,DB00989,Rivastigmine
,33466880,T50%,In vitro release studies revealed that the optimal RV-ISM system released 100% of its drug content throughout a release period of 30 days with only 15.5% drug release within the first day (Q1) and T50% of 13.09 days.,In Situ-Forming Microparticles for Controlled Release of Rivastigmine: In Vitro Optimization and In Vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33466880/),d,13.09,110086,DB00989,Rivastigmine
,33466880,injection rate,"Moreover, the optimal system showed a high injection rate of 1.012 mL/min, pseudoplastic flow, uniform spherical globules with homogenous particle size, minimal cytotoxicity and high tolerability to γ-sterilization.",In Situ-Forming Microparticles for Controlled Release of Rivastigmine: In Vitro Optimization and In Vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33466880/),[ml] / [min],1.012,110087,DB00989,Rivastigmine
,27639640,Absolute bioavailability (F),"Absolute bioavailability (F) of the nasal spray was significant at 0.62 (0.15) for F > 0 (P < 0.001, n = 8).",Absolute bioavailability and safety of a novel rivastigmine nasal spray in healthy elderly individuals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27639640/),,0.62,128775,DB00989,Rivastigmine
,27639640,systemic dose absorbed,"The systemic dose absorbed was 2.0 (0.6) mg, time to maximum plasma concentration was 1.1 (0.5) h and maximum plasma concentration was 6.9 (2.0) ng ml-1 .",Absolute bioavailability and safety of a novel rivastigmine nasal spray in healthy elderly individuals. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27639640/),mg,2.0,128776,DB00989,Rivastigmine
,27639640,time to maximum plasma concentration,"The systemic dose absorbed was 2.0 (0.6) mg, time to maximum plasma concentration was 1.1 (0.5) h and maximum plasma concentration was 6.9 (2.0) ng ml-1 .",Absolute bioavailability and safety of a novel rivastigmine nasal spray in healthy elderly individuals. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27639640/),h,1.1,128777,DB00989,Rivastigmine
,27639640,maximum plasma concentration,"The systemic dose absorbed was 2.0 (0.6) mg, time to maximum plasma concentration was 1.1 (0.5) h and maximum plasma concentration was 6.9 (2.0) ng ml-1 .",Absolute bioavailability and safety of a novel rivastigmine nasal spray in healthy elderly individuals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27639640/),[ng] / [ml],6.9,128778,DB00989,Rivastigmine
,27639640,AUC0-∞ ratio,The NAP226-90 to rivastigmine AUC0-∞ ratio was 0.78 (0.19).,Absolute bioavailability and safety of a novel rivastigmine nasal spray in healthy elderly individuals. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27639640/),,0.78,128779,DB00989,Rivastigmine
,29294189,absolute bioavailability,"In present work, we have selected Rivastigmine hydrogen tartrate (RHT), a reversible cholinesterase inhibitor, which exhibits extensive first-pass metabolism, resulting in limited absolute bioavailability (36%).",Formulation and In-vivo Pharmacokinetic Consideration of Intranasal Microemulsion and Mucoadhesive Microemulsion of Rivastigmine for Brain Targeting. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29294189/),%,36,143378,DB00989,Rivastigmine
,28923321,entrapment efficiency,"NLCs having particle size of 123.2 ± 2.3 nm, entrapment efficiency of 68.3 ± 3.4%, and zeta potential of 32 ± 1.2 mV was fabricated by a scalable method.",Nose to Brain Delivery of Rivastigmine by In Situ Gelling Cationic Nanostructured Lipid Carriers: Enhanced Brain Distribution and Pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923321/),%,68.3,162988,DB00989,Rivastigmine
,28923321,zeta potential,"NLCs having particle size of 123.2 ± 2.3 nm, entrapment efficiency of 68.3 ± 3.4%, and zeta potential of 32 ± 1.2 mV was fabricated by a scalable method.",Nose to Brain Delivery of Rivastigmine by In Situ Gelling Cationic Nanostructured Lipid Carriers: Enhanced Brain Distribution and Pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923321/),mv,32,162989,DB00989,Rivastigmine
,28923321,blood brain barrier penetrating potential,Biodistribution indicated blood brain barrier penetrating potential of IV NLCs (457.24 ± 38.41.12 ng/mL) and IN NLCs (736.42 ± 34.54 ng/mL) with 4.6 and 5.3-fold enhancement in brain concentrations compared with IV and IN solution of RV.,Nose to Brain Delivery of Rivastigmine by In Situ Gelling Cationic Nanostructured Lipid Carriers: Enhanced Brain Distribution and Pharmacodynamics. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923321/),[ng] / [ml],457.24,162990,DB00989,Rivastigmine
,28923321,blood brain barrier penetrating potential,Biodistribution indicated blood brain barrier penetrating potential of IV NLCs (457.24 ± 38.41.12 ng/mL) and IN NLCs (736.42 ± 34.54 ng/mL) with 4.6 and 5.3-fold enhancement in brain concentrations compared with IV and IN solution of RV.,Nose to Brain Delivery of Rivastigmine by In Situ Gelling Cationic Nanostructured Lipid Carriers: Enhanced Brain Distribution and Pharmacodynamics. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28923321/),[ng] / [ml],736.42,162991,DB00989,Rivastigmine
,18001519,area under the,"However, drug exposure (area under the curve; AUC) was not significantly different between the 4.6 mg/24 hour (5 cm(2)) patch and 3 mg BID (6 mg/day) capsule doses, or between the 9.5 mg/24 hour (10 cm(2)) patch and 6 mg BID (12 mg/day) capsule doses, according to both analyses.",Rivastigmine exposure provided by a transdermal patch versus capsules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18001519/),,9.5,195324,DB00989,Rivastigmine
,34086100,Tmax,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),min,5,204525,DB00989,Rivastigmine
,34086100,Cmax,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),,1489.5,204526,DB00989,Rivastigmine
,34086100,systemic bioavailability (F,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),,118.65,204527,DB00989,Rivastigmine
,34086100,AUC,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),,"35,921.75",204528,DB00989,Rivastigmine
,34086100,half-life,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),min,30.92,204529,DB00989,Rivastigmine
,34086100,Tmax,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),min,15,204530,DB00989,Rivastigmine
,34086100,Cmax,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),,56.29,204531,DB00989,Rivastigmine
,34086100,F,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),,4.39,204532,DB00989,Rivastigmine
,34086100,AUC,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),,1663.79,204533,DB00989,Rivastigmine
,34086100,t1/2,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),,13.48,204534,DB00989,Rivastigmine
,34086100,Kel (,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),[1] / [min],0.0514,204535,DB00989,Rivastigmine
,29932610,absolute bioavailability,The absolute bioavailability of intranasally administrated RHT was 73.58%.,[Intranasal absorption of rivastigmine hydrogen tartrate and brain targeting evaluation]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29932610/),%,73.58,206959,DB00989,Rivastigmine
,28415883,entrapment efficiency percentage,"A medium nano-sized liposome (478 ± 4.94 nm) with a nearly neutral zeta potential (ZP, -8 ± 0.2 mV) and an entrapment efficiency percentage of 48 ± 6.22 was prepared.","Electrosteric stealth Rivastigmine loaded liposomes for brain targeting: preparation, characterization, ex vivo, bio-distribution and in vivo pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28415883/),,48,239126,DB00989,Rivastigmine
,28415883,relative bioavailability,On completing the in vivo pharmacokinetic studies of 36 rabbits showed 424.2% relative bioavailability of the mean plasma levels of the formula ESS compared to that of RHT intranasal solution and 486% relative bioavailability of the mean brain levels.,"Electrosteric stealth Rivastigmine loaded liposomes for brain targeting: preparation, characterization, ex vivo, bio-distribution and in vivo pharmacokinetic studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28415883/),%,424.2,239127,DB00989,Rivastigmine
,28415883,relative bioavailability,On completing the in vivo pharmacokinetic studies of 36 rabbits showed 424.2% relative bioavailability of the mean plasma levels of the formula ESS compared to that of RHT intranasal solution and 486% relative bioavailability of the mean brain levels.,"Electrosteric stealth Rivastigmine loaded liposomes for brain targeting: preparation, characterization, ex vivo, bio-distribution and in vivo pharmacokinetic studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28415883/),%,486,239128,DB00989,Rivastigmine
,9737824,bioavailability,"Extensive, saturable first-pass metabolism, however, leads to bioavailability of approximately 35% of the administered dose and nonlinear pharmacokinetics.",Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737824/),%,35,252131,DB00989,Rivastigmine
,22010358,entrapped efficiency,"The entrapped efficiency of rivastigmine liposome was (33.41 +/- 6.58) %, with the mean diameter of 154-236 nm and zeta potential of (-10.47 +/- 2.41) mV.",[Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22010358/),%,33.41,254059,DB00989,Rivastigmine
,22010358,zeta potential,"The entrapped efficiency of rivastigmine liposome was (33.41 +/- 6.58) %, with the mean diameter of 154-236 nm and zeta potential of (-10.47 +/- 2.41) mV.",[Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22010358/),mv,-,254060,DB00989,Rivastigmine
,22010358,zeta potential,"The entrapped efficiency of rivastigmine liposome was (33.41 +/- 6.58) %, with the mean diameter of 154-236 nm and zeta potential of (-10.47 +/- 2.41) mV.",[Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22010358/),mv,10.47,254061,DB00989,Rivastigmine
,22010358,C(max),"The pharmacokinetic studies indicated that the C(max), T(max) and AUC(0-infinity), of rivastigmine liposome were (1.50 +/- 0.15) mg x L(-1), 15 min and (89.06 +/- 8.30) mg x L(-') x min, respectively.",[Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22010358/),[mg] / [l],1.50,254062,DB00989,Rivastigmine
,22010358,T(max),"The pharmacokinetic studies indicated that the C(max), T(max) and AUC(0-infinity), of rivastigmine liposome were (1.50 +/- 0.15) mg x L(-1), 15 min and (89.06 +/- 8.30) mg x L(-') x min, respectively.",[Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22010358/),min,15,254063,DB00989,Rivastigmine
,22010358,AUC(0-infinity),"The pharmacokinetic studies indicated that the C(max), T(max) and AUC(0-infinity), of rivastigmine liposome were (1.50 +/- 0.15) mg x L(-1), 15 min and (89.06 +/- 8.30) mg x L(-') x min, respectively.",[Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22010358/),l(-')·mg·min,89.06,254064,DB00989,Rivastigmine
